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Objectives: The objective of this study was to propose an optimal treatment regimen of meropenem in critically ill
patients with severe nosocomial pneumonia.
Patients and methods: Among 55 patients in intensive care treated with 1 g of meropenem every 8 h for severe
nosocomial pneumonia, 30 were assigned to intermittent infusion (II; over 0.5 h) and 25 to extended infusion
(EI; over 3 h) groups. Based on plasma and epithelial lining fluid (ELF) concentrations determined at steady-
state, pharmacokinetic modelling and Monte Carlo simulations were undertaken to assess the probability
of attaining drug concentrations above the MIC for 40%–100% of the time between doses (%T.1-fold and
4-fold MIC), for 1 or 2 g administered by either method.
Results: Penetration ratio, measured by the ELF/plasma ratio of AUCs, was statistically higher in the EI group than
in the II group (mean+SEM: 0.29+0.030 versus 0.20+0.033, P¼0.047). Considering a maximum susceptibility
breakpoint of 2 mg/L, all dosages and modes of infusions achieved 40%–100% T.1-fold MIC in plasma, but
none did so in ELF, and only the 2 g dose over EI achieved 40%–100% T.4-fold MIC in plasma.
Conclusions: The optimum regimen to treat severe nosocomial pneumonia was 2 g of meropenem infused over
3 h every 8 h. This regimen achieved the highest pharmacodynamic targets both in plasma and in ELF.
Keywords: epithelial lining fluid concentrations, Monte Carlo simulations, critically ill patients
Introduction
Severe nosocomial pneumonia in patients in ICUs is caused by a
wide range of bacteria and is associated with high rates of mor-
bidity and mortality, as well as high costs.1,2 In this setting,
prompt use of b-lactams remains the cornerstone of antibiotic
therapy, and among these drugs, meropenem is often chosen
because it is well tolerated and has a wide spectrum of activity.
Meropenem is a time-dependent antibiotic: maintaining
unbound drug concentrations in plasma above the MIC for patho-
gens for at least 40% of the time between doses (≥40% T.MIC)
is usually required for optimal bactericidal activity.3,4 In serious
bacterial infections this goal could be extended to 100% of the
dosing interval,5 – 7 so that extended infusion (EI, i.e. dose deliv-
ered over several hours) or even continuous infusion (i.e. dose
delivered over 24 h) has been proposed in place of the usual inter-
mittent infusion (II, i.e. over a few minutes) to improve pharma-
cokinetic (PK) and pharmacodynamic (PD) properties.5 – 13
Furthermore, drug concentration at the site of infection seems
to influence efficacy.3,4 Dosage of antibiotics in the epithelial lining
fluid (ELF) is advocated as the best marker of drug exposure at the
site of infection in patients with pneumonia, particularly for extra-
cellular respiratory tract pathogens, although this method has
some limitations.14 – 17
Because PK data can be difficult to obtain, especially at the site
of infection, population PK modelling and Monte Carlo simulations
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have been developed to predict PK/PD profiles of several antibio-
tics for a large number of subjects, including ICU patients.12,13,18
Aims
The aim of the PROMESSE (PROtocol MEropenem Steady State
Evaluation) study, performed in critically ill patients with severe
nosocomial pneumonia, was to determine whether EI (over 3 h)
of 1 g of meropenem every 8 h offered PK/PD advantages in plasma
and ELF in comparison with II (over 0.5 h), in order to predict an
optimal treatment regimen in this setting. After collecting drug
concentrations in plasma and ELF, we used a population model
to describe the PK variability of meropenem concentrations and
we performed Monte Carlo simulations to assess the probability
of target attainment (PTA) for the two different modes of infusion
for a range of PK/PD breakpoints and MICs for extracellular
Gram-negative pathogens that are likely to be encountered in ICUs.
Patients and methods
Study design and participants
This was a single-centre, open-label, prospective comparative study that
was conducted in five ICUs, with a total of 42 medical and surgical
beds, at the Centre Hospitalier Universitaire du Sart Tilman, Lie`ge,
Belgium between January and September 2012. The study was approved
by the local ethics committee, and informed consent was obtained from
close relatives of the patients because all patients were ventilated at the
time of inclusion.
Eligible patients had to meet the following inclusion criteria: age
.18 years; diagnosis of late-onset (.5 days after admission) ventilator-
associated pneumonia or hospital-acquired pneumonia requiring mech-
anical ventilation; and glomerular filtration rate (GFR)≥30 mL/min (calcu-
lated according to the four-variable Modification of Diet in Renal Disease
formula19 or by measurement of creatinine clearance based on 24 h
urine) or acute kidney injury with indication for continuous venovenous
haemofiltration (CVVH). The following exclusion criteria were used: preg-
nancy; life expectancy ,3 days; allergy to b-lactams; GFR ,30 mL/min
and no required CVVH; previous use of meropenem within 15 days; and
colonization with pathogens known to be resistant to meropenem.
The definition of pneumonia required clinical criteria and/or a simplified
clinical pulmonary infection score≥6 points.20,21 Clinical criteria were: new
or progressive radiological pulmonary infiltrate plus two or more of tem-
perature .38 or ,35.58C, leucocyte count .12000 or ,4000 cells/mm3 or
purulent respiratory secretions.20
Data collection
In addition to GFR estimation, various demographic and clinical data were
collected, including age, sex, weight, duration of hospital stay and/or ICU
stay before onset of pneumonia, and the presence of severe sepsis, septic
shock, concomitant bacteraemia, liver cirrhosis and surgical drain.
Simplified acute physiology score (SAPS) III and SOFA score were calcu-
lated at the onset of pneumonia. Crude 30 day mortality and in-hospital
mortality were also collected.
Treatment and sampling
Assignment of patients to treatment groups was initially performed in a
sequential manner, followed by a third phase of recruitment to ensure that
the exact numbers of patients defined in the protocol were reached in each
group. Patients from this phase were arbitrarily assigned treatment by a
named operator. Meropenem (Meronemw, AstraZeneca Pharmaceuticals,
Belgium) was administered as either II (infusion over 0.5 h) in 30 patients
(II group) or EI (infusion over 3 h) in 25 patients (EI group), at a dose of 1 g
every 8 h, which is usually recommended in nosocomial pneumonia.1 The
drug was dissolved in 50 mL of 0.9% saline solution and injected into a central
venous catheter via a volumetric pump with an infusion dead space
of ,2 mL.22
All plasma and ELF samples were obtained at steady-state, i.e. after at
least three doses. The times of the start of infusion, end of infusion and sam-
pling were recorded by intensive care nurses. Samples were excluded from
the analysis if they were not collected within 15 min either side of the
expected time of sampling. Blood samples (2 mL) were collected from
indwelling arterial catheters before and 0.5, 1, 3, 4 and 6 h after the start
of meropenem infusion. Simultaneously, ELF samples (one per patient)
were collected by a standardized mini-bronchoalveolar lavage (mini-BAL)
procedure with 2×20 mL of sterile 0.9% normal saline solution, using a
non-bronchoscopic BAL catheter (Bal-Cathw system, Kimberly Clark,
Zaventem, Belgium), with all of the samples being collected by the same
operator.15 Patients were assigned to subgroups of five patients per time-
point to cover the whole PK profile in ELF (i.e. six within the II group and
five within the EI group as only II patients underwent mini-BAL at 0.5 h).
Blood and ELF samples were immediately centrifuged at 3000 rpm for
10 min; the supernatant was immediately separated and kept at –808C
until analysis. After sampling, a switch to an alternative regimen was sys-
tematically considered with the infectious diseases physician to promote
de-escalation based on the clinical, radiological, biological and microbio-
logical results.
Analytical methods
Concentrations of meropenem in plasma and ELF were measured with a
simple and rapid UPLC method with ultraviolet detection.23 Briefly, 50 mL
of plasma (or 2 mL of ELF) was spiked with cefamandole, which was used
as an internal standard, and cleaned up by solid-phase column extraction
prior to UPLC analysis. The extracted samples were analysed using an
Acquity UPLC BEH C18 column (100×2.1 mm i.d., 1.7 mm, Waters, MA,
USA) with a mobile phase consisting of a methanol and ammonium for-
mate buffer mixture in gradient mode. Ultraviolet detection was set at
300 nm, and the total run time was 13 min. The method developed was
linear over the concentration range of 1.0–180.0 mg/L in plasma and
0.01–2.0 mg/L in ELF. Between- and within-run accuracy and precision
were all within 15%.23 The unbound (free) fraction of meropenem was
not measured, but we believed that this was not necessary as the drug
has a low protein binding of 2%–8%.4,12
The concentrations of urea in the plasma and ELF were determined
with the Urea Nitrogen/1900 kit (Roche Professional Diagnostics,
Mannheim, Germany). Urea was hydrolysed in the presence of urease in
ammonia and carbon dioxide. Then ammonia was combined with
2-oxoglutarate and NADH in the presence of the enzyme glutamate
dehydrogenase. This reaction produced L-glutamate and NAD+. The
urea concentration was directly proportional to the rate of decrease in
the NADH concentration, which was determined by absorption spectros-
copy at 340 nm. Limits of quantification were 0.06 and 0.01 g/L in the
plasma and ELF, respectively. The concentration of meropenem in ELF
was thereafter determined using urea as an endogenous marker, accord-
ing to the following formula:15
MERELF = MERBAL×ureaPLAureaBAL
where MERELF is the concentration of meropenem in ELF, MERBAL is the con-
centration of meropenem in the mini-BAL fluid, ureaPLA is the concentra-
tion of urea in plasma (collected concomitantly with bronchoscopy) and
ureaBAL is the concentration of urea in the mini-BAL fluid.
PK analysis
Non-compartmental analysis was performed for descriptive purposes, to
explore preliminary data and to generate an objective basis to enable
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comparison of our findings with previously published results on penetra-
tion ratios in ELF.24 – 26 The AUCs in the plasma and ELF were computed
using the linear trapezoidal rule. Individual AUCs were calculated for
each patient’s plasma sample (the value considered at the end of the dos-
ing interval was the same as that measured at time 0 because no samples
were drawn at that point and steady-state was deemed to have been
reached) and were compared by classical Student’s t-test. Since each
patient underwent one mini-BAL and there were five patients per time-
point, only one AUC in ELF could be calculated in each group (EI and II)
based on the mean values at each timepoint. The AUC in plasma was
also calculated in each group as done for ELF, i.e. based on the same
five patients at each timepoint. This allowed calculation of the penetration
ratio, measured by the ELF/plasma AUC ratio. To compare the penetration
ratio in the II and EI groups, the bootstrap method was used to derive
SEMs of the estimates.
A population PK model was developed to enable Monte Carlo simula-
tions to be performed for the subsequent PK/PD analysis. A non-linear
mixed-effects modelling approach was performed with NONMEM,
version 7.2 (double precision, Icon Development Solutions, Ellicott
City, MD, USA) and PsN-toolkit version 3 (a programming library for non-
linear mixed-effects modelling).27,28 Briefly, the first-order conditional
estimation approach with interaction between parameters was used
throughout the entire modelling process, and one-, two- and three-
compartment structural models were tested. PK parameters were
estimated with NONMEM in terms of intercompartmental clearance
(Q, L/h), clearance from the central compartment (L/h) and volumes
Table 1. Demographic, clinical and microbiological data of the 55 patients
All (n¼55) II group (n¼30) EI group (n¼25) P
Demographic and clinical data
male 35 (63.6) 17 (56.7) 18 (72.0) 0.24
age (years) 63.4+15.1 61.5+17.9 65.7+10.9 0.31
weight (kg) 78.4+18.4 82.3+19.9 73.7+15.4 0.084
hospital stay before onset of pneumonia (days) 17.3+18.1 15.9+18.5 18.9 17.9 0.54
ICU stay before onset of pneumonia (days) 8.4+10.7 9.6+12.8 7.0+7.4 0.37
clinical criteria of pneumonia 46 (83.6) 27 (90.0) 19 (76.0) 0.16
simplified CPIS ≥6 52 (94.5) 30 (100.0) 22 (88.0) 0.088d
SAPS IIIa 74.8+13.5 73.4+13.7 76.5+13.3 0.40
SOFA scorea 7.7+4.1 7.7+4.1 7.6+4.0 0.98
severe sepsis 39 (70.9) 19 (63.3) 20 (80.0) 0.18
septic shock 12 (21.8) 5 (16.7) 7 (28.0) 0.31
concomitant bacteraemia 12 (21.8) 3 (10.0) 9 (36.0) 0.02
liver cirrhosis 6 (10.9) 3 (10.0) 3 (12.0) 0.81
CLCR (MDRD)
.60 mL/min 31 (56.4) 17 (56.7) 14 (56.0) 0.73
30–59 mL/min 13 (23.6) 8 (26.7) 5 (20.0)
CVVH 11 (20.0) 5 (16.7) 6 (24.0)
CVVH with residual renal function 2 (3.6) 1 (3.3) 1 (4.0) 0.91
CLCR (using the urine of 24 h)
not performed 13 (23.6) 7 (23.3) 6 (24.0) 0.34
.120 mL/min 17 (30.9) 12 (40) 5 (20.0)
119–60 mL/min 11 (20.0) 4 (13.3) 7 (28.0)
,60 mL/min 14 (25.5) 7 (23.3) 7 (28.0)
presence of surgical drains 18 (32.7) 10 (33.3) 8 (32.0) 0.92
30 day mortality 21 (38.2) 12 (40.0) 9 (36.0) 0.76
in-hospital mortality 30 (54.5) 17 (56.7) 13 (52.0) 0.73
antibiotic de-escalation 35 (63.6) 17 (56.7) 18 (72.0) 0.24
number of doses before sampling 6.5+4.1 6.8+4.2 6.2+4.0 0.59
Microbiological data; susceptibility testing: S/I/R (%)b
P. aeruginosa 8 (87.5/0/12.5) 5 3 0.43
A. baumannii 1 (0/0/100) 1 0 0.31
Enterobacteriaceae [ESBL] 29 (100/0/0) [6] 13 [3] 16 [3] 0.25
total of Gram-negative bacteria 38c 19 19 0.99
CPIS, clinical pulmonary infectious score; MDRD, Modification of Diet in Renal Disease formula.
The values are presented as n (%) or the mean+SD.
aCalculated at the onset of pneumonia.
bBased on EUCAST breakpoints (S≤2; R.8 mg/L): S, susceptible; I, intermediate; and R, resistant.
cThirty-eight Gram-negative bacteria isolated in 35 patients (two Enterobacteriaceae isolated simultaneously in three subjects).
dFisher’s exact test.
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of distribution (L) of the different compartments, using conventional
equations. An additional compartment was added each time to model
the ELF concentrations.
The interindividual variability in the PK parameters was estimated
with the use of an exponential model, and all parameters were initially
tested. Additive, proportional and mixed error models were tested for
residual error. A full model approach was implemented for covariate
model building with age, sex, weight, presence of severe sepsis, septic
shock, concomitant bacteraemia, liver cirrhosis, surgical drain, SAPS
III, SOFA score and creatinine clearance (GFR) tested as covariates on
volumes of distribution and/or clearance parameters. Allometric and
multiplicative functions were used for continuous and categorical vari-
ables, respectively. The model stability and accuracy were evaluated by
bootstrapping, normalized prediction distribution errors and visual pre-
dictive check.29
PD analysis and Monte Carlo simulations
On the basis of the population PK model, simulations were created
with NONMEMw, and concentrations of meropenem in plasma and ELF
were generated for 5000 virtual subjects for each of four scenarios: 1 or
2 g administered by II and 1 or 2 g administered by EI every 8 h.
Subsequently, the % T.MIC values in plasma and ELF were calculated
for each virtual subject. The 90% PTA was obtained by counting the sub-
jects who achieved 40%, 54% and 100% T.1-fold and 4-fold MICs, ran-
ging from 0.0625 to 64.0 mg/L. Bactericidal activity of meropenem is
usually 40% T.1-fold MIC,3,4 but some authors consider that the maximal
bactericidal effect of b-lactams (including meropenem) occurs when con-
centrations exceed the MIC by up to 5-fold for up to 100% of the dosing
interval, particularly in critically ill patients and/or for pathogens with high
MICs.4 –6 For this reason we assessed PD targets at 40%, 54% and 100%
T.1-fold or 4-fold MIC. We selected 54% T.MIC because it is the PD clin-
ical breakpoint threshold chosen by EUCAST for meropenem,30 based on the
findings of Li et al.31 We used the breakpoints defined by EUCAST for
Pseudomonas spp., Acinetobacter spp. and Enterobacteriaceae (suscepti-
bility, intermediate and resistance thresholds of ≤2, 4–8 and .8 mg/L,
respectively).30
Statistical analysis
Data were summarized as mean and SD for quantitative variables while
frequency tables were used for the categorical findings. Mean values
were compared by one-way analysis of variance and the x2 test was
used to compare proportions. For comparing the penetration ratio in the
two study groups, a Z-test was used based on the SEMs derived from
the bootstrap method. Results were considered significant at the 5% crit-
ical level (P,0.05). Data analysis was carried out using the SAS (version
9.3 for Windows) and S-PLUS (version 8.1) statistical packages.
Results
Patient enrolment, exclusions and adverse events
Among 63 patients enrolled, five patients in the II group were
excluded during treatment (ureaBAL undetectable in three sub-
jects, massive desquamation and unexpected high concentration
of meropenem in the mini-BAL fluid in one and inversion of
plasma samples in one), as were three in the EI group (ureaBAL
undetectable in two subjects and moderate haemorrhage and
unexpected high concentration of meropenem in the mini-BAL
fluid in one). Therefore, eight patients were included in the
third enrolment phase to complete each treatment group.
Meropenem and mini-BAL were well tolerated without any signifi-
cant adverse events.
Patients’ demographic, clinical, PK and
microbiological data
The patients’ demographic, clinical and microbiological character-
istics are described in Table 1. No significant differences were
observed in the evaluated parameters, except for a trend towards
higher weight and lower concomitant bacteraemia in the II
patients. The eight patients included in the third enrolment
phase had the same demographic and diseases profile as other
patients. Increased risk of death at 30 days was associated with
bacteraemia (OR 7.75, 95% CI: 1.79–33.6; P¼0.006), severe sep-
sis (OR 6.65, 95% CI: 1.33–33.2; P¼0.021) and high SAPS III (OR
1.06, 95% CI: 1.02–1.10; P¼0.0036) in the univariate analysis
and with bacteraemia (OR 16.6, 95% CI: 2.04–136; P¼0.0086),
high SAPS III (OR 1.07, 95% CI: 1.02–1.13; P¼0.0085) and the
II group (OR 4.90, 95% CI: 0.92–26.3; P¼0.063) in the multivari-
ate analysis.
Sampling was performed after a median of six doses of mero-
penem (range 3–22), with no statistically significant difference
between the two groups. Eleven patients received CVVH, and
30.9% had augmented renal clearance (.120 mL/min) with
GFR calculated using 24 h urine (n¼42). Forty-six pathogens
were isolated from 41 patients (23 from 21 patients in the II
group; 23 from 20 patients in the EI group; two different patho-
gens were isolated in five subjects), no pathogens were cultured
from the remaining nine (30%) II patients and five (20%) EI
patients and this was not statistically significant. Six of the patho-
gens were Gram-positive (three methicillin-susceptible and two
methicillin-resistant Staphylococcus aureus; one Streptococcus
pneumoniae) and were excluded. Among the Gram-negative bac-
teria, Haemophilus influenzae was identified twice (one patient
in each group), and this bacterium was not tested against mero-
penem; therefore, 38 bacteria were considered as invasive for
microbiological analysis (29 Enterobacteriaceae, 8 Pseudomonas
aeruginosa and 1 Acinetobacter baumannii). The distribution of
MICs for P. aeruginosa was as follows: ≤ 0.25 mg/L, four strains;
0.5 mg/L, two strains; 1 mg/L, one strain; .8 mg/L, one strain.
The results of the AUC in plasma, AUC in ELF and penetration
ratio are presented in Table 2. The mean values of AUC0 – 24 of
meropenem concentrations in plasma were similar in the two
groups (422+48.3 and 502+67.0 mg.h/L in the II group and
the EI group, respectively; P¼0.26), but concentrations in ELF
Table 2. Comparison of AUC in plasma and ELF
Parameter II group EI group P
All patientsa (n¼30, II group; n¼25, EI group)
AUC0 – 24 in plasma (mg.h/L) 422+48.3 502+67.0 0.26
Patients at each timepoint (n¼5)b
AUC0 – 24 in plasma (mg.h/L) 396+37.7 515+68.4 0.082
AUC0 – 24 in ELF (mg.h/L) 80.3+11.8 150+24.2 0.010
ELF/plasma penetration ratio 0.20+0.033 0.29+0.030 0.047
The values are presented as the mean+SEM. SEM values were derived by
the bootstrap method.
aAUC in plasma calculated for each patient in each group.
bCalculated using ELF and plasma data of the five patients who underwent
mini-BAL at each timepoint.
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were significantly lower in the II group than in the EI group
(80.3+11.8 versus 150.0+24.2 mg.h/L; P¼0.010). Consequently,
the AUC penetration ratio was higher in the EI group than in the
II group (0.29+0.030 versus 0.20+0.033) and this was statistically
significant (P¼0.047).
Subjects with creatinine clearance .120 mL/min had a
significantly lower AUC in plasma than subjects with creatinine
clearance ,120 mL/min in both groups: mean+SEM 226+16.8
versus 561+77.7 mg.h/L in the II group (P,0.0001) and
201+25.4 versus 467+60.4 mg.h/L in the EI group (P,0.0001),
respectively. It was not possible to compare the AUC in ELF
between the two groups due to the small number of patients
(e.g. EI group and creatinine clearance .120 mL/min, n¼5).
A high PK interindividual variability was observed in the
plasma and ELF concentrations in both groups, as observed in
Figure 1.
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Figure 1. Observed steady-state concentrations of 1 g of meropenem every 8 h in plasma and ELF. II group, 0.5 h infusion rate; n¼30. EI group, 3 h
infusion rate; n¼25. 0.0¼pre-dose sampling. (a) Interindividual variability observed in plasma (six samples per patient) in both II and EI groups. (b) Mean
plasma concentration–time curves (+SD) observed in both II and EI groups. (c) Interindividual variability observed in ELF (one sample per patient, five
patients per timepoint, except at 0.5 h where only II patients underwent mini-BAL) in both II and EI groups.
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Model building
PK modelling was performed with the data from 375 (99.2%)
of the expected 378 plasma samples and 55 ELF samples. A two-
compartment model provided an adequate fit to the plasma data.
An additional compartment was added to describe ELF concen-
trations. PK parameters were described in terms of systemic clear-
ance, volume of the central compartment (Vc), volume of the
peripheral compartment (Vp), volume of the ELF compartment
(VE) and intercompartmental clearance (Q). Interindividual vari-
ability components were necessary to describe the clearance
and the volume of distribution terms. A mixed model was retained
for residual errors with proportional and additive components.
Body weight was retained as a significant covariate on volumes
of the central compartment whereas creatinine clearance was a
significant covariate on total clearance. Estimated shrinkage was
found to be,20% for all random effects parameters. Model para-
meters including bootstrap results are presented in Table 3.
Goodness-of-fit plots show that the model adequately fitted
plasma and ELF concentrations, as displayed in Figure 2 and
Figure S1 (available as Supplementary data at JAC Online). Good
overlap between the observed and predicted plasma and
mini-BAL concentrations indicates that the model predicts out-
comes well and is suitable for use in Monte Carlo simulations.
The developed model was used to simulate concentrations in
plasma and ELF that could serve as a basis from which to com-
pute % T.MIC as a PK/PD parameter of interest.
Monte Carlo simulations and PD analysis
The proportion of simulated subjects in which PTA would be
achieved was ≥90% of patients for several PK/PD targets (40%,
54% or 100% T.MIC) against a range of MICs in plasma and
ELF for the different meropenem doses (1 versus 2 g) and meth-
ods of infusion [II (0.5 h) versus EI (3 h)] and is displayed in
Figure 3. The corresponding PK/PD breakpoints are summarized
in Table 4. Universally, two parameters were observed: first, the
PK/PD breakpoints were one dilution higher with EI than with II
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Figure 1. Continued
Table 3. Population PK model characteristics
Parameter Final model estimate Bootstrap CI
TVCL (L/h) 10.2 8.3–10.9
TVQE (L/h) 66.5 7.3–9.9
TVQP (L/h) 6.9 5.32–8.55
TVVc (L) 5.2 4.3–5.1
TVVp (L) 12.1 2.6–40.1
TVVE (L) 11.3 10.1–12.6
QWT on Vc 0.6 0.41–0.79
QGFR on CL 0.73 0.38–0.86
sprop 0.2 0.1–0.2
sadd 0.8 0.7–0.9
TVCL, typical value for renal clearance; TVQE, typical value for the inter-
compartmental clearance between the central and ELF compartments;
TVQP, typical value for the intercompartmental clearance between the
central and peripheral compartments; TVVc, typical value for the volume
of the central compartment; TVVp, typical value for the volume of the per-
ipheral compartment; TVVE, typical value for the volume of the ELF com-
partment; QWT on Vc, allometric effect of the total body weight on the
volume of the central compartment; QGFR on CL, allometric effect of
GFR on renal clearance; sprop, proportional error; sadd, additive error.
Frippiat et al.
212
 by Paul Tulkens on D
ecem
ber 17, 2014
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
for a defined dose (e.g. for 1 g and a PD target of 40% T.MIC, the
PK/PD breakpoints were 4 and 0.5 mg/L with EI and 2 and 0.25
mg/L with II in plasma and ELF, respectively); and second, similar
results were obtained for 2 g given over 0.5 h and for 1 g given over
3 h every 8 h, both in plasma and ELF. A notable exception to these
two parameters was present when considering 100% T.1-fold
or 4-fold MIC as a target, where there was no difference between
the two modes of administration (except for 2 g in plasma where
the PK/PD breakpoint remained one dilution higher with EI than
with II). Of note, no difference was observed between the PD tar-
gets of 40% or 54% T.MIC in any scenario. The lowest PK/PD
breakpoint in ELF was 0.06 mg/L (for 1 g over 0.5 h with a thera-
peutic target of 40%–100% T.4-fold MIC) and the highest was
1.0 mg/L (for 2 g over 3 h and a therapeutic target of 40%–54%
T.1-fold MIC).
Thus, considering the EUCAST susceptibility breakpoint of
2 mg/L, all dosages and both modes of infusion reached the tar-
gets from 40% to 100% T.1-fold MIC in plasma, but not in ELF.
Only the 2 g dose over 3 h achieved a 4-fold MIC (i.e. 8 mg/L) in
plasma from 40% until 100% of the dosing interval.
Discussion
This study, performed with meropenem in patients with severe
nosocomial pneumonia, showed a significant higher AUC pene-
tration ratio with EI than with II and better PK/PD parameters
both in plasma and in ELF with 2 g infused over 3 h every 8 h.
Contrary to what was done in most of previously published
studies on the topic,15,16,24 – 26 the penetration of meropenem
in ELF was only described using the ratio between the AUC
in ELF and the AUC in plasma, rather than comparing concentra-
tions simultaneously obtained in plasma and ELF at individual
timepoints. This was done since the equilibrium between the
compartments does not occur instantaneously, and the concen-
tration–time profiles of antibiotics in plasma and ELF can increase
and decrease at different paces from each other (known as
system hysteresis): penetration ratios may therefore vary in mag-
nitude with the chosen sampling times.16,32
To date, three studies have been conducted to assess PK/PD
characteristics for meropenem in ELF,24 – 26 but only one was
conducted in critically ill patients with ventilator-associated
pneumonia and using AUC penetration ratios.26 The ELF-to-plasma
penetration ratios of 1 g of meropenem infused over 0.5 h ranged,
depending on the sampling time considered, from 0.32 to 0.53
in healthy volunteers after multiple doses,25 and from 0.19 to
1.04 in patients without acute pneumonia undergoing diagnostic
bronchoscopy after a single dose.24 These results were higher
than ours (range from 0.11 to 0.32 in the II group and from
0.12 to 0.49 in the EI group, data not shown). By contrast, a
study performed in patients with ventilator-associated pneumo-
nia who received ertapenem at steady-state showed penetration
ratios ranging from 0.28 to 0.46,15 and another study of healthy
volunteers who received single-dose biapenem showed a mean
penetration ratio of 0.20 for both 0.5 and 3 h infusions.33
On the basis of the ratios of the AUC, Lodise et al.26 found mean
and median penetration ratios of 0.82 and 0.26, respectively, in
patients with ventilator-associated pneumonia when they
performed a 9999-subject Monte Carlo simulation for single-dose
2 g meropenem given over 3 h. In that study, substantial vari-
ability in the penetration ratio was shown with 10th and 90th
percentiles being 3.7% and 178.0%, respectively, without
clear physiological explanation. Finally, using a microdialysis-
based approach, Tomaselli et al.34 found a lung interstitial
fluid-to-serum AUC ratio of 0.41+0.21 in seven patients with
pneumonia and metapneumonic pleural empyema treated by
decortications. In summary, our findings confirm those from pre-
vious studies,15,24 – 26,33,34 objectifying a relatively low ELF/plasma
penetration ratio of 0.2–0.3 for carbapenems in comparison with
other b-lactams.16,26,35
The PK characteristics of meropenem in plasma described
in the present study are similar to those from previous studies
performed in critically ill ICU patients with or without
pneumonia.10 – 12,36 – 39 The total volume of distribution was
large (28.6 L) due to the high proportion of patients with severe
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Figure 2. Fit of the model to the observed data for (a) the plasma
concentration (mg/L) and (b) the ELF concentration (mg/L) for
meropenem in ICU patients with severe nosocomial pneumonia.
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illness (severe sepsis, septic shock and bacteraemia present in 71%,
22% and 22%, respectively), and drug clearance was low (10.2 L/h)
due to globally decreased renal function (creatinine clearance
30–59 mL/min in 23.6% and CVVH required in 20% of patients).12
Analysis of urine samples collected after 24 h revealed acceler-
ated renal clearance (.120 mL/min) in 31% of patients. This
variability in renal function is possibly the most important factor
that could account for the high interindividual variability in con-
centrations in plasma and ELF between the two groups.5,12,26
The PK/PD parameter that correlates with efficacy ofb-lactams
is the proportion of the dosing interval during which the concen-
tration of unbound (free) drug in plasma remains above the MIC
of a specific pathogen (% T.MIC). For meropenem the threshold
value is widely considered to be 40% T.1-fold MIC,3,4 but recent
clinical data found that values of 54%–76% T.MIC are also pre-
dictive of clinical and microbiological responses in patients with
infections of the lower respiratory tract.31,36 Some authors con-
sider that the maximal bactericidal effect of b-lactams (including
meropenem) occurs when concentrations exceed the MIC by up
to 5-fold for up to 100% of the dosing interval, particularly in crit-
ically ill patients and/or for pathogens with high MICs.5 – 7 For this
reason we assessed PD targets at 40%, 54% and 100% T.1-fold
or 4-fold MIC. We selected 54% T.MIC because it is the PD clinical
breakpoint threshold chosen by EUCAST for meropenem,30 based
on the findings of Li et al.31 Our results showed no difference
between PD targets of 40% or 54% in any scenario. Similar results
were obtained in plasma and ELF using 2 g over 0.5 h and 1 g over
3 h, except for a PD target of 100% T.MIC, where no advantage
of EI over II was observed in the ELF.
Considering EUCAST breakpoints,30 our data suggest that sus-
ceptible pathogens (MICs of up to 2 mg/L) could be successfully
treated with 1 g of meropenem infused over 0.5 h every 8 h if
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Figure 3. Target attainment rates in ELF (left) and plasma (right) after different dosing regimens: continuous black line with black circles: 1 g, 0.5 h
infusion; continuous light grey line with light grey circles: 1 g, 3 h infusion; broken black line with black triangles, 2 g, 0.5 h infusion; and continuous
grey line with grey triangles, 2 g, 3 h infusion.
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the 40–100% T.1-fold MICs are taken to be the relevant PK/PD
targets in plasma. However, 2 g infused over 3 h every 8 h would
be required to reach the same PK/PD target (i.e. in plasma)
for pathogens that have intermediate susceptibility (MICs of
8 mg/L) or for susceptible pathogens when PK/PD targets of
40%, 54% and 100% T.4-fold MIC are required. Notably, 1 g
infused over 0.5 h every 8 h is usually recommended for patients
with nosocomial pneumonia, but not 2 g infused over 3 h every
8 h.1 In contrast, for ELF, our study shows that EUCAST suscepti-
bility breakpoints are not reached since PK/PD breakpoints range
from 0.06 to 1.0 mg/L, depending on the dose, duration of infusion
and PK/PD target selected. Reaching sufficient concentrations at
the infected site seems a logical prerequisite for efficacy,16,17,35
but no clinical study has yet documented the possible correlations
between ELF and plasma concentrations and clinical or microbio-
logical outcomes.5,16,17 Consequently, caution must be applied in
presuming that the magnitudes of the PD parameters in ELF are
the same as those proposed for plasma.16
The limitations associated with this evaluation include first its
single-centre and non-randomized design. Second, we were not
able to analyse the impact of the type of infusion’s modality on
the mortality, since only crude mortality was collected, microbio-
logical evolution was lacking (such as bacterial load reduction or
occurrence of failure and/or resistance during meropenem treat-
ment) and de-escalation was performed in 63.6% of cases after
3.0+1.3 days. Third, our data were collected from a 1 g dosing
regimen and simulations were performed for 1 and 2 g dosing
regimens, using a model developed with a data-driven approach.
This latter assumed linear PK of meropenem, such as observed in
plasma over a dose range of 250–2000 mg.40 However, a study
performed in healthy volunteers showed that plasma concentra-
tions increased proportionally with doses of meropenem, while
concentrations in ELF tended to decrease as meropenem doses
increased, without clear explanation.25 Fourth, whilst renal func-
tion and body weights of the study subjects were heterogeneous,
owing to inclusion of patients requiring CVVH and those with
accelerated renal function, the PK/PD analysis was performed glo-
bally. Finally, as many patients in our study were severely ill, the
results might not be applicable to all ICU populations. This
range of patients, however, reflects real life in the ICU.
In conclusion, with regard to penetration ratios of the AUC and
PD targets observed both in plasma and in ELF, better results were
obtained with EI than with II. Meropenem should be used empir-
ically at the dosage of 2 g infused over 3 h every 8 h to treat severe
nosocomial pneumonia occurring in the ICU until identification of
a specific aetiological pathogen. These conclusions should be con-
firmed and validated in a larger prospective study investigating
the correlation between PK/PD parameters in ELF and plasma
and clinical and microbiological outcomes to assess if the magni-
tudes of exposure required in ELF are similar to those observed in
plasma.
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Supplementary data 
 
Figure S1. Visual predictive check plots. 
 
 
Left panel: intermittent infusion group, right panel: extended infusion group. Upper panels: plasma 
data, lower panels, epithelial lining fluid data. Grey circles: observed concentrations. Grey lines:  95% 
prediction intervals of the observed concentrations (2.5, 50 and 97.5 percentiles on the observed 
concentrations). Black lines: simulated 95% prediction intervals of the simulated concentrations in 
200 simulated patients, dotted lines: 2.5% percentiles, continuous line: median, dash line: 97.5% 
percentiles.  
 
 
